Lakeside Holding partners with Huiyu Pharma in oncology drug distribution

Lakeside Holding (LSH) announced that its recent acquisition in China, Hupan Pharmaceutical, has entered into a strategic distribution agreement with Sichuan Huiyu Pharmaceutical, a company dealing in oncology and immune-related therapies, listed on the Shanghai Stock Exchange. Hupan Pharmaceutical will distribute Huiyu Pharmaceutical’s oncology and immunotherapy drugs to hospitals and healthcare institutions to domestic and global markets. Huiyu Pharmaceutical’s flagship product, Pemetrexed Disodium for Injection, has received regulatory approvals in major markets, including China, the UK, Germany, and Finland.